A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour.

Trial Profile

A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2013

At a glance

  • Drugs Gemcitabine elaidate (Primary) ; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Aqualis
  • Most Recent Events

    • 04 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
    • 15 Sep 2008 Patient enrolment is ongoing on CP 4126 1400 mg/m2/day to establish the recommended phase II dose.
    • 13 Sep 2008 Promising results presented at the European Society for Medical Oncology meeting in September
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top